Dova is a growing specialty pharmaceutical company driven by our passion for building a high-value portfolio of differentiated medicines for patients with rare diseases. Every day we work to develop and commercialize solutions that can improve patients' health and well-being in this community. The US FDA approved Dova's lead drug product in May 2018, and in June 2019, the FDA approved a second indication. In June 2019, Dova also received its first approval in the EU. Dova is headquartered in Durham, North Carolina. The company is a wholly-owned subsidiary of Swedish Orphan Biovitrum AB (publ) (Sobi).